Full Press Release Details
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025.
In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 3, 2025.
The live audio webcast and accompanying slides may be accessed through theEvents & Presentations pagein the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following:
Conference ID: Syndax3Q25Domestic Dial-in Number: 800-590-8290International Dial-in Number: 240-690-8800Live webcast:https://sndx-3q25.open-exchange.net
For those unable to participate in the conference call or webcast, a replay will be available on the Investors section of the Company's website atwww.syndax.comapproximately 24 hours after the conference call and will be available for 90 days following the call.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj®(revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visitwww.syndax.comor follow the Company onXandLinkedIn.Syndax Contact
Sharon KlahreSyndax Pharmaceuticals, Inc.sklahre@syndax.comTel 781.684.9827SNDX-G